Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury (original) (raw)
Fig 5
Effects of dapagliflozin on HIF1 in HK2 cells.
(A) Representative Western blot: dapagliflozin increased HIF1 expression and phosphorylation of AMPK and ERK in hypoxic HK2 cells. *P < 0.05 vs., dapagliflozin nontreated normoxic HK2 cells, #P < 0.05 vs. normoxic HK2 cells. **P < 0.05 vs. control hypoxic HK2 cells. (B) Representative Western blot: hypoxia increased HIF1 expression and decreased SGTL2 expression. Dapagliflozin pretreatment decrease SGLT2 expression in hypoxic HK2 cells. *P < 0.05 vs., dapagliflozin nontreated normoxic HK2 cells, #P < 0.05 vs. normoxic HK2 cells. **P < 0.05 vs. control hypoxic HK2 cells. (C) Dapaglilfozin pretreatment increase HIF1 expression in normoxic and hypoxic HK2 cells compared to control and hypoxic control HK2 cells respectively. Albendazole decreased HIF1 expression in dapagliflozin-treated hypoxic HK2 cells. *P < 0.05 vs., control HK2 cells, #P < 0.05 vs.control hypoxic HK2 cells. **P < 0.05 vs. albendazole nontreated—dapagliflozin treated hypoxic HK2 cells. (D) Albendazole decreased cell survival in dapagliflozin-treated hypoxic HK2 cells. *P < 0.05 vs., control hypoxic HK2 cells #P < 0.05 vs.dapagliflozin treated hypoxic HK2 cells. (E) Dapagliflozin decreased glucose uptake in hypoxic HK2 cells. *P < 0.05 vs., hypoxic HK2 cells. Bar represents mean ± s.d. All cellular experiment repeated three times for western blot, cell viability test, and glucose uptake test.